2001 Clinical Trials Patients Terpenes 
The Cannigma
JANUARY 13, 2023
Based on the limited existing evidence, the best cannabis strain for migraines may be a Type II that includes both THC and CBD, and a terpene profile that includes beta-caryophyllene, myrcene, linalool, limonene, bisabolol, humulene or pinene. The study called out pinene, myrcene, and beta-caryophyllene as specifically useful terpenes.
CannaTech
SEPTEMBER 16, 2018
Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. Doctors have remained integral parts of a patient’s cannabis journey through what is known as the Access to Cannabis for Medical Purposes Regulation (ACMPR) act. The Need for Cannabis Education Tailored to Patient and Doctor.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. No hepatic side effects were noted.
Cannabis Law Report
JUNE 4, 2021
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. Brian Muraresku. in/ingmargorman/ [link]. in/cgwitowski/ [link]. Bruce Tobin.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.
Expert insights. Personalized for you.
132 
Let's personalize your content